Thomas Miller, PhD

Vice President, Clinical Development
Enalare Therapeutics Inc.

Poster(s):

• 105: ENA-001, a Novel BK-channel Blocker, Enhances Hypoxic Ventilatory Sensitivity and Alleviates Propofol-induced Respiratory Effects in Healthy Volunteers
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET

• 148: The Mechanism of Action of an Innovative Respiratory Stimulant, ENA-001
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET